Activity ID



June 3, 2022

Format Type


CME Credit



$0 - $75

CME Provider: University of California, Irvine School of Medicine

Description of CME Course

This is a two-day colloquium that will include both the 10th Annual UC Irvine Neuromuscular Colloquium and on day two the 6th Annual UC Irvine Pathology Colloquium.

The program has been developed and tailored based on areas of new disease-related information identified by the Planning Committee with further input from the faculty panel and recent advances in the literature relating to neuromuscular diseases. As an example, recent successful trials have led to FDA approval of new drugs for the treatment of Myasthenia Gravis, Duchenne Muscular Dystrophy, Spinal Muscular Atrophy.

The recent approval of novel immune modulatory therapy in Myasthenia Gravis has opened up new possibilities in terms of time of intervention as well as treatment outcomes for disease exacerbations, crises, and even refractory disease. This has led to several new investigational therapies in the pipeline for the coming year and these therapies are likely to eventually lead to treatment paradigm changes.

Register for this Activity

ABMS Member Board Approvals by Type
More Information
Commercial Support?

NOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.

Educational Objectives

1. Describe the ongoing in-human gene therapy trials in myotubular myopathy and their preliminary results.
2. Identify different clinical presentations and patterns of involvement in neuromuscular diseases.
3. Describe current diagnostic and management strategies in rare and orphan neuromuscular diseases.
4. Recognize the potential systemic complications in these disorders.
5. List current standards and guidelines for management.
6. Explain the difference between primary inflammatory myopathies vs. myopathies secondary to connective tissue disease.
7. Identify features helpful in distinguishing acquired myopathies from inherited myopathies.
8. Identify features on muscle pathology that help prognosticate for cancer or interstitial lung disease.


Myotubular, Myopathy, Myasthenia Gravis, Neuropathology


Interpersonal & Communication Skills, Medical Knowledge, Patient Care & Procedural Skills, Practice-based Learning & Improvement, Systems-based Practice

CME Credit Type

AMA PRA Category 1 Credit

Practice Setting

Academic Medicine, Inpatient, Outpatient, Rural, Urban, VA/Military

View All Activities by this CME Provider

The information provided on this page is subject to change. Please refer to the CME Provider’s website to confirm the most current information.